The CTSA Program is designed to strengthen and support the entire spectrum of translational research from scientific discovery to improved patient care. Read the latest in CTSA Program news about improving the quality and efficiency of translational research, particularly multisite clinical trials.
- February 2019
- December 2018
- November 2018
- August 2018
- July 2018
- June 2018
- April 2018
- December 2017
- November 2017
- October 2017
- July 2017
- April 2017
- March 2017
- February 2017
- December 2016
- October 2016
- September 2016
- June 2016
- May 2016
- February 2016
- September 2015
- May 2015
- February 2015
- May 2014
- October 2013
- January 2013
- March 2012
CTSA Program Supports Emerging Research on Health Effects of Plastics
An early-career investigator has developed techniques to study how chemicals used in medical devices affect the still-developing hearts of pediatric patients. Program support also enabled her to secure independent funding for larger studies.
A Model for Accelerating Translational Research in Real Time
Investigators from the CTSA Program hub at the Medical College of Wisconsin have devised and piloted an innovative approach called Real-Time IRB that reduces the time between study submission to the institutional review board and final approval by 70 percent.
NCATS-Supported Research Shows Potential for Altering Body Fat
CTSA Program-supported researchers at Columbia University have discovered a new way to take white fat from a mouse, turn it into brown fat and return it to the mouse. These findings could have implications for treating obesity.
CTSA Program Researchers Shed Light on Improved Melanoma Treatment
Researchers at the University of California, Los Angeles, a CTSA Program hub, discovered four subtypes of melanoma — pointing to new treatment approaches.
NCATS-Supported Study Highlights Troubling Trend in Opioid Prescribing
Researchers at the University of California, Los Angeles, supported in part by NCATS' CTSA Program, discovered a troubling opioid prescribing trend. Patients who took a type of anti-anxiety medicine were more than twice as likely as the general public to receive new opioid prescriptions despite a higher overdose risk.
CTSA Program Support May Lead to Blood Test for Colon Cancer Screening
University of Alabama at Birmingham researchers, supported in part by NCATS’ Clinical and Translational Science Awards (CTSA) Program, teamed up with scientists from the HudsonAlpha Institute for Biotechnology to identify markers in the blood that could be used to detect precancerous polyps in patients.
New Study Shows Medication-Based Treatment After Opioid Overdose Can Save Lives
Researchers from Boston University, a CTSA Program hub, have found a strong link between the use of medications to treat opioid use disorder and a reduced risk of overdose death. CTSA Program funding supported statistical analysis for this study, which also included support from NIH’s National Institute on Drug Abuse.
CTSA Program Researchers Advance Heart Condition Study Through Precision Medicine and Digital Health
Researchers at the Scripps Translational Science Institute in San Diego, a CTSA Program hub, are working to address the challenge of diagnosing atrial fibrillation, a common heart condition with complex causes. The team’s efforts can ultimately help advance precision medicine approaches to preventing and diagnosing other types of complex diseases.
CTSA Program Support Enables Innovative Study of Brain Function
A CTSA Program-funded researcher tests innovative training to help people with schizophrenia “correct” disordered brain waves. Promising results suggest the training could potentially help improve memory.
CTSA Program Supports Research on Translating Evidence into Practice
CTSA Program-supported researchers explore the dissemination and clinical implementation of therapies, interventions and policies to ultimately improve human health.
CTSA Program-Supported Investigators Validate Biomarkers for NPC1 Treatment
With support from the Sharing Partnership for Innovative Research in Translation (SPIRiT) consortium, Daniel Ory, M.D., of Washington University in St. Louis, and Charles Vite, D.V.M., Ph.D., of the University of Pennsylvania, collaborated to validate biomarkers intended to monitor the response to therapy for Niemann-Pick diseases type C1 (NPC1).
CTSA Program-Supported Researchers Test Low-Cost Treatment for Deadly Illness
Virginia Commonwealth University researchers have discovered a low-cost and potentially lifesaving treatment for sepsis. Support from the CTSA Program helped streamline translation of this promising therapy to multisite clinical studies.
NCATS Supports Novel Methods to Improve Institutional Review Board Efficiencies
NCATS’ Clinical and Translational Science Awards Program support helped a University of Wisconsin–Madison Ph.D. student discover new ways of identifying factors affecting institutional review board (IRB) review times.
NCATS Trial Innovation Network Investigators Tackling Clinical Trial Inefficiencies
Through NCATS’ new Trial Innovation Network, CTSA Program-supported investigators are working collaboratively to tackle inefficiencies in clinical trials.
NCATS SMART IRB Platform Agreement
All CTSA Program sites have signed on to the NCATS Streamlined, Multisite, Accelerated Resources for Trials (SMART) Institutional Review Board (IRB) Platform agreement, which will enable all participating study sites to rely on one IRB for each study.
North Carolina CTSA Program Hubs Create Regulatory Expertise Platform
Three North Carolina CTSA Program hubs collaborated to create a platform for sharing regulatory expertise. Regulatory Guidance for Academic Research of Drugs and Devices features a best practices website to help researchers better navigate the complex regulatory environment in translational science.
CTSA Program Good Clinical Practice Standards Published
Investigators leading the CTSA Program good clinical practice (GCP) standards initiative published three papers in the Journal of Clinical and Translational Science. GCP incorporates established ethical and scientific quality standards for the design, conduct, recording and reporting of clinical research involving human subjects.
Optimizing Translational Veterinary Trials to Advance Human Outcomes
The CTSA One Health Alliance has established a primary mission of creating an organized network of veterinary academic centers that will conduct translational clinical trials in veterinary patients with spontaneous disease.
SPARC: The Strategic Pharma-Academic Research
The Strategic Pharma-Academic Research Consortium aims to spark innovative collaborations between CTSA Program hubs and the biopharmaceutical industry. The vision is to establish a public-private partnership for patient-focused discoveries that generate greater knowledge and better approaches to next-generation and targeted therapies.
NCATS Presents Early Plans for Trial Innovation Network, Solicits Project Proposals
Efforts to align and harmonize three Trial Innovation Centers and the Recruitment Innovation Center are underway within the NCATS Trial Innovation Network, a new collaborative initiative made possible through the CTSA Program.
NCATS Launches Trial Innovation Network
NCATS launches its Trial Innovation Network, which features a single institutional review board system, master contracting agreements, quality-by-design approaches, and a focus on evidence-based strategies for recruitment and patient engagement.
NCATS Funds Collaborative Innovation Awards
In fall 2016, NCATS funded the first set of CTSA Program Collaborative Innovation Awards, which are designed to stimulate team-based research across the program’s network.
CTSA Program Supports New Ultrasensitive Diagnostic Test Development
Stanford University researchers have developed a new test for diagnosing diseases, including thyroid cancer, HIV and type 1 diabetes. The method appears to be many times more sensitive than some traditional diagnostic tests, meaning that it potentially can detect illnesses earlier, enabling clinicians to treat patients sooner and possibly slow disease progression.
CTSA Program Resources Help UCLA Scientists Visualize Key Enzyme in Cancer and Aging
With support from NCATS’ CTSA Program, scientists at the University of California, Los Angeles (UCLA), recently produced the clearest-ever image of telomerase, an enzyme involved in cancer and aging. This knowledge could inform the development of anti-cancer and anti-aging therapies.
NCATS Introduces Plans for New Single IRB Reliance Platform
On May 2, 2016, NCATS held a workshop for CTSA Program representatives and other innovators in clinical research management to educate them about using its new single institutional review board (IRB) reliance platform for multisite clinical studies.
CTSA Program Collaboration Provides Investigators with Access to High-Throughput Screening and Drug Discovery Expertise
CTSA Program hub researchers at the University of New Mexico, the University of Kansas Medical Center, and the University of North Carolina, Chapel Hill, collaborated to establish the Drug Rescue, Repurposing and Repositioning Network to more rapidly test existing drugs and advance those showing promise into clinical trials.
Progress Toward a National CTSA Program Institutional Review Board Reliance Agreement
CTSA Program investigators made progress toward creating IRBrely, a national institutional review board (IRB) reliance agreement to streamline the review and approval of multisite clinical trials.
Michigan CTSA Program Supports Development of Blood Analysis Device
A Michigan research team funded in part by NCATS’ CTSA Program and the National Heart, Lung, and Blood Institute has developed a life-saving diagnostic device that can test extremely small blood samples.
CTSA Program Supports Streamlined Clinical Trial Recruitment
Researchers at the University of New Mexico Clinical and Translational Science Center recently established the Participant Recruitment Service. Supported through NCATS’ CTSA Program, the goal is to streamline and improve recruitment rates for clinical trials while maintaining patient privacy.
CTSA Initiative Yields Standard Agreement for Industry-Sponsored Clinical Trials
A standard agreement intended to reduce the contract negotiation time for industry-sponsored multisite studies, including Phase IIB and Phase III trials, is now available to download.
Creating Review Standards for Investigator-Initiated Research Studies
The NCATS Scientific Review Standards initiative aims to develop a consensus CTSA Program scientific review process that can ensure feasibility and scientific validity for research projects before reviews by institutional review boards.
Establishing Good Clinical Practices for Clinical Study Personnel
At the February 2015 CTSA Program principal investigators meeting, Thomas Shanley, M.D., of the University of Michigan shared progress and next steps for the CTSA Program’s Good Clinical Practice initiative.
IRB Reliance: A New Model for Accelerating Translational Science
Within the CTSA Program, several institutions are participating in institutional review board (IRB) reliance networks to streamline this complicated process.
Five CTSA Program Hubs Enable NIH-Funded Research on Innovative Allergy Therapy
Finding a new way to treat and possibly prevent the severest food allergy reactions could improve the lives of millions. A consortium of scientists at five institutions that receive NIH funding, including through NCATS’ CTSA Program, took up this challenge.
Pitt Researchers Work to Restore Function in Paralysis Patients
A team of researchers at the University of Pittsburgh and its medical center have published breakthrough brain-computer-interface research that provides hope to nearly 6 million paralyzed individuals and another 1.7 million amputees nationwide.
Converting Brain Signals into Action
A multidisciplinary team of researchers at the University of Pittsburgh received critical help from CTSA Program regulatory experts to develop a micro-electrocorticography grid that may help paralyzed individuals move again.
Designing Solutions to Improve Health for All
A team in Stanford University’s Biodesign program designed the OneBreath ventilator for use in emergency pandemic situations and for patient care in resource-poor countries.